We have built a large, expert team to design and manage our clinical trials, the vital and lengthy phase following discovery and preclinical development.
Our Clinical Development and Regulatory Affairs group has more than 400 team members, including many with doctoral degrees and years of pharmaceutical-industry experience.
Peter Powchik, M.D.
SVP, Clinical Development
Bola Akinlade, M.D., M.B.A., F.A.C.P.
Executive Director, Clinical Sciences
Ned Braunstein, M.D.
SVP, Regulatory Affairs
Ingrid Adamsons, M.D., M.P.H.
VP Pharmacovigilance and Risk Management
Graeme Currie, Ph.D.
VP Clinical Project Management and Operations
Israel Lowy, M.D., Ph.D.
VP Translational Science and Oncology
Daniel Matarazzo, M.B.A.
Senior Director Clinical Finance
Scott Mellis, M.D., Ph.D.
VP Clinical Sciences, Translational Medicine
Robert Pordy, M.D., FACP
VP Clinical Sciences, Cardiovascular and Metobolism
Yuhwen Soo, Ph.D.
VP Biostatistics and Data Management
Catherine Stehman-Breen, M.D., M.S.
VP Clinical Sciences
Beate Stych, M.D.
VP Medical Affairs
Janet van Adelsberg, M.D.
Senior Director, Immunology and Inflammation
Robert Vitti, M.D., M.B.A.
VP Clinical Sciences, Ophthalmology